Successful treatment with belimumab of severe systemic lupus erythematosus not responding to standard therapy: a case report

Successful treatment with belimumab of severe systemic lupus erythematosus not responding to standard therapy: a case report

Authors

  • Ottavia Magnani Department of Internal Medicine, Clinical Immunology Unit, IRCCS-AOU San Martino IST, Genova, Italy
  • Elena Penza Department of Internal Medicine, Clinical Immunology Unit, IRCCS-AOU San Martino IST, Genova, Italy
  • Giuseppe Murdaca Department of Internal Medicine, Clinical Immunology Unit, IRCCS-AOU San Martino IST, Genova, Italy
  • Francesco Puppo Department of Internal Medicine, Clinical Immunology Unit, IRCCS-AOU San Martino IST, Genova, Italy

DOI:

https://doi.org/10.7175/cmi.v10i1.1227

Keywords:

Systemic Lupus Erythematosus (SLE), Belimumab, Biological Therapy

Abstract

 

Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by complex pathophysiology and heterogeneous clinical picture. Belimumab is the first biological therapy licensed for SLE.

We report the case of a 24 years old woman affected by a severe form of systemic lupus erythematosus with arthritis, muscle weakness, cervical lymphadenopathy, cutaneous involvement, fever, leukopenia, low complement levels and positivity for anti-dsDNA antibodies. Treatment with high dose steroids, hydroxychloroquine, and mycophenolate mofetil did not induce remission and several disease flares were observed. Therapy with anti-BLys monoclonal antibody belimumab leads to a fast clinical and laboratory response and to stable remission lasting for 30 months allowing steroid tapering to very low maintenance dose. 

References

Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-21; y of hepatitis B. Semin Liver Dis 2005; 25: 3-8; http://dx.doi.org/10.1056/NEJMra1100359

Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86; http://dx.doi.org/10.1002/art.34473

Kuhn A, Bonsmann G, Anders H, et al. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int 2015; 112: 423-32; http://dx.doi.org/10.3238/arztebl.2015.0423

Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205; http://dx.doi.org/10.1136/ard.2007.070367

Burness CB, McCormack PL. Belimumab: in systemic lupus erythematosus. Drugs 2011; 71: 2435-44; http://dx.doi.org/doi:10.2165/11208440-000000000-00000

Hahn BH. Belimumab for Systemic Lupus Erythematosus. N Engl J Med 2013; 368: 1528-35; http://dx.doi.org/10.1056/NEJMct1207259

Wallace DJ, Navarra S, Petri MA, et al. for the BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013; 22 : 144-54; http://dx.doi.org/10.1177/0961203312469259.

Ginzler EM, Wallace DJ, Merrill JT, et al. for the LBSL02/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014; 41 : 300-9; http://dx.doi.org/10.3899/jrheum.121368

Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53: 1470-76 http://dx.doi.org/10.1093/rheumatology/keu148

Downloads

Published

2016-03-31

Issue

Vol. 10 No. 1 (2016)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)